Tech Is Getting Left Behind in the S&P 500’s Latest Rebound

The S&P 500 has moved back to within a hair of its Oct. 28 record high, but the rebound is not being driven by Big Tech: the S&P 500 Information Technology index is down 4.2% since that date. Healthcare and other non-tech names are leading the gains — Eli Lilly, Cardinal Health and Biogen rank among the top 10 performers since Oct. 28 — while Magnificent Seven stocks such as Nvidia and Microsoft have seen larger declines, indicating a sector rotation that could influence near-term positioning.

Analysis

Market structure: the current rebound is breadth-driven with Healthcare (Eli Lilly, Cardinal Health CAH, Biogen BIIB) capturing flows while the S&P Information Technology index is -4.2% since Oct. 28. Direct beneficiaries are cash-generative, defensive healthcare distributors and late-cycle pharma names that trade on stable cashflows and M&A optionality; losers are high-multiple growth tech (Magnificent Seven—NVDA, MSFT) facing short-term multiple compression and higher options-implied volatility (+100–200bps expected).

Risk assessment: tail risks include an AI-driven earnings re-acceleration that re-rates tech (high-impact, <30% probability) and regulatory/drug setbacks for BIIB or operational supply disruptions at CAH (low-probability, high-impact). Near term (days) expect vol spikes around earnings and Fed/CPI prints; short-term (weeks–months) index rebalances and flow rotations matter; long-term (quarters–years) fundamentals (AI revenue ramps, drug approvals) will dominate valuations. Hidden dependencies: passive indexing and leveraged tech ETFs can amplify moves; Cardinal Health exposure to hospital capex and pharma inventory cycles is underappreciated.

Trade implications: favor tactical overweight to healthcare (CAH, BIIB, XLV) and defensive distributors, while hedging or trimming concentrated tech exposure. Use option structures to protect against fast tech rebounds (buy puts or put spreads on NVDA/XLK) rather than naked shorts; employ pair trades to capture relative momentum. Key catalysts: upcoming earnings seasons, quarter-end ETF rebalances, and any Fed communication—act within the next 5–20 trading days and reassess after those events.

Contrarian view: consensus treats tech weakness as secular—this may be overstated; a single strong AI earnings cadence could produce >15–25% snapback in NVDA/MSFT, making outright short positions asymmetric. Conversely, healthcare crowding could flip quickly if macro growth data surprises to the upside or if bond yields lift; size positions and use hard stop-losses and option hedges to manage convex risk.

Key Decisions for Investors

• Establish a 2–3% long position in Cardinal Health (CAH) within the next 5 trading days, target +12% in 3 months, initial stop-loss at -8%; increase to 4–5% if next quarterly revenue/EBITDA beats consensus by >3%.
• Initiate a 1–2% long position in Biogen (BIIB) as an event-driven hold into the next 3–6 month pipeline/earnings window; hedge downside with a 6-month 25% OTM put sized to limit loss to ~10% of the position value.
• Implement a relative-value rotation: overweight Healthcare ETF (XLV) by +3% and underweight Technology ETF (XLK) by -3% within 10 trading days; take profits if XLV outperforms XLK by +5% in 30 days or trim if XLK rebounds >5%.
• Buy short-dated protection on concentrated tech exposure: allocate 0.5–1% of portfolio to 3–6 week puts on NVDA (5%–10% OTM) or an equivalent XLK put to cap tail risk; prefer debit put spreads to control premium if IV is elevated.